252 related articles for article (PubMed ID: 33332545)
1. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
Isler B; Harris P; Stewart AG; Paterson DL
J Antimicrob Chemother; 2021 Feb; 76(3):550-560. PubMed ID: 33332545
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
3. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
Abdelraouf K; Almarzoky Abuhussain S; Nicolau DP
J Antimicrob Chemother; 2020 Dec; 75(12):3601-3610. PubMed ID: 32862218
[TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
6.
Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
[TBL] [Abstract][Full Text] [Related]
7. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
8.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
9. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in
Hamrick JC; Docquier JD; Uehara T; Myers CL; Six DA; Chatwin CL; John KJ; Vernacchio SF; Cusick SM; Trout REL; Pozzi C; De Luca F; Benvenuti M; Mangani S; Liu B; Jackson RW; Moeck G; Xerri L; Burns CJ; Pevear DC; Daigle DM
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871094
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
[TBL] [Abstract][Full Text] [Related]
11. Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
Mushtaq S; Vickers A; Doumith M; Ellington MJ; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 Jan; 76(1):160-170. PubMed ID: 33305800
[TBL] [Abstract][Full Text] [Related]
12.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
13.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
14. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
15. Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in
Kloezen W; Melchers RJ; Georgiou PC; Mouton JW; Meletiadis J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431413
[TBL] [Abstract][Full Text] [Related]
16. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
17. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
[TBL] [Abstract][Full Text] [Related]
18. The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli.
Roach EJ; Uehara T; Daigle DM; Six DA; Khursigara CM
Microbiol Spectr; 2021 Oct; 9(2):e0091821. PubMed ID: 34494877
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM
Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512
[TBL] [Abstract][Full Text] [Related]
20. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
Lasko MJ; Nicolau DP; Asempa TE
J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]